ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Clinical practice"

  • Abstract Number: 3181 • 2015 ACR/ARHP Annual Meeting

    How Common Is Inactive Disease in a Prospective Cohort of Patients with Juvenile Idiopathic Arthritis? the Importance of Definition

    Stephanie Shoop1, Suzanne M. Verstappen2, Eileen Baildam3, Alice Chieng4, Joyce Davidson5,6, Helen Foster7, Yiannis Ioannou8, Flora McErlane7, Lucy R Wedderburn9, Wendy Thomson10 and Kimme L. Hyrich10, 1ARC Epidemiology, Stopford Building, ARC Epidemiology Unit, The University of Manchester, M13 9PT, United Kingdom, 2ARC Epidemiology, Stopford Building, ARC Epidemiology Unit, the University of Manchester, Manchester, United Kingdom, 3Paediatric Rheumatology, Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom, 4Royal Manchester Children's Hospital, Manchester, United Kingdom, 5The Royal Hospital for Sick Children, Glasgow, Glasgow, United Kingdom, 6The Royal Hospital for Sick Children, Edinburgh, Edinburgh, United Kingdom, 7Royal Victoria Hospital, Newcastle, United Kingdom, 8Rayne Institute, University College London, London, UK, London, United Kingdom, 9Great Ormond Street Hospital NHS Foundation Trust, Paediatric Rheumatology, London, United Kingdom, 10arc Epidemiology Unit, Manchester, United Kingdom

    Background/Purpose: Patients with JIA are at risk of disability, pain and joint damage in the longer-term. Treating toward clinically inactive disease (ID) has the potential…
  • Abstract Number: 504 • 2015 ACR/ARHP Annual Meeting

    Influence of CDAI Measurement on the Decision of Community Rheumatologists to Initiate or Change Biologic Treatment

    Alan K. Matsumoto1, Herbert S. B. Baraf2, Janna Radtchenko3, Jason Drenning4 and Bruce Feinberg5, 1Rheumatology, Arthritis & Rheumatism Assoc, Wheaton, MD, 2The Center for Rheumatology and Bone Research, Wheaton, MD, 3Health Care Analytics, Cardinal Health, Dallas, TX, 4Healthcare Analytics, Cardinal health, Dallas, TX, 5Cardinal Health, Dublin, OH

    Background/Purpose: Periodic measurement of disease activity using validated tools such as the Clinical Disease Activity Index (CDAI) is considered an important aspect of care for…
  • Abstract Number: 3185 • 2015 ACR/ARHP Annual Meeting

    A Cluster-Randomized Trial of a Behavioral Intervention to Incorporate a Treat-to-Target Approach in the Clinical Care of Rheumatoid Arthritis Patients in the United States

    Leslie Harrold1,2, George W. Reed1,2, J. Timothy Harrington3, Christine J. Barr1, Katherine C. Saunders1, Allan Gibofsky4, Eric M. Ruderman5, Tmirah Haselkorn6, Jeffrey D. Greenberg1,7, Ani John6 and Joel M. Kremer8, 1Corrona, LLC, Southborough, MA, 2University of Massachusetts Medical School, Worcester, MA, 3Joiner Associates, LLC, Madison, WI, 4Hospital for Special Surgery, New York, NY, 5Medicine, Division of Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, 6Genentech, Inc, South San Francisco, CA, 7NYU School of Medicine, New York, NY, 8Albany Medical College and The Center for Rheumatology, Albany, NY

    Background/Purpose: We report the results of a cluster-randomized behavioral intervention trial designed to assess the impact of implementing a treat-to-target (T2T) approach vs usual care…
  • Abstract Number: 506 • 2015 ACR/ARHP Annual Meeting

    Evaluation of Persistence and Outcomes in Patients Treated with TNF and Non-TNF Biologics Following Treatment Clinical Pathway in Rheumatoid Arthritis

    Alan K. Matsumoto1, Herbert S. B. Baraf2, Janna Radtchenko3, Jason Drenning4 and Bruce Feinberg5, 1Rheumatology, Arthritis & Rheumatism Assoc, Wheaton, MD, 2The Center for Rheumatology and Bone Research, Wheaton, MD, 3Health Care Analytics, Cardinal Health, Dallas, TX, 4Healthcare Analytics, Cardinal health, Dallas, TX, 5Cardinal Health, Dublin, OH

    Background/Purpose: Use of biologic agents for the treatment of rheumatoid arthritis continues to grow rapidly, with the cost of these agents putting a significant strain…
  • Abstract Number: 580 • 2015 ACR/ARHP Annual Meeting

    Treatment with Biologic Agents in Rheumatoid Arthritis and Mortality Risk in Clinical Practice

    Leticia Leon1, Luis Rodriguez-Rodriguez1, Alejandro Gomez-Gomez2, Pilar Macarrón2, Margarita Blanco2, Juan A Jover2 and Lydia Abasolo1, 1Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain, 2Rheumatology, Hospital Clínico San Carlos, Madrid, Spain

    Background/Purpose: It is a well-known fact the decline of life expectancy in Rheumatoid Arthritis (RA) being the increased mortality in these patients a constant concern…
  • Abstract Number: 682 • 2015 ACR/ARHP Annual Meeting

    Misalignment Between Physician and Patient Satisfaction with Current Psoriatic Arthritis Treatment

    Daniel E. Furst1, Emma Sullivan2, James Pike3, James Piercy4, Jacqueline Palmer5 and Vivian Herrera5, 1Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 2Adelphi Real World, Manchester, United Kingdom, 3Statistics, Adelphi Real World, Macclesfield, United Kingdom, 4Adelphi Real World, Macclesfield, United Kingdom, 5Novartis Pharmaceuticals Corporation, East Hanover, NJ

    Background/Purpose: Psoriatic Arthritis (PsA) is a chronic immune related condition affecting the joints and commonly occurs alongside psoriasis. Well-established physician patient relationships are instrumental to…
  • Abstract Number: 1276 • 2015 ACR/ARHP Annual Meeting

    Improvement in Work and Household Productivity for Patients with Rheumatoid Arthritis and Ankylosing Spondylitis Treated with Anti-TNFs in Routine Clinical Practice in Turkey

    Sebnem Ataman1, Mehmet Kirnap2, Buminhan Seferoglu3, Zuhal Altay4, Aylin Rezvani5, Omer Kuru6,7, Erhan Capkin8, Nazli Derya Bugdayci9, Ilhan Sezer10, Hasan Fatih CAY11 and Akinci Tan12, 1Rheumatology Department, Ankara University Faculty of Medicine, Ankara, Turkey, 2Department of Physical Medicine and Rehabilitation, Erciyes University, Kayseri, Turkey, 3Physical Medicine and Rehabilitation, Ataturk University Medical School, Erzurum, Turkey, 4ELAZIG KARAYOLU UZERI, Inonu University, Turgut Ozal Medical Center, Malatya, Turkey, 5Department of Physical Medicine and Rehabilitation, Bezmialem Foundation University, İstanbul, Turkey, 6Kurupelit Mevkii Kurupelit 552, Ondokuz Mayis Univ.Tip Fak.Has.-Fizik Tedavi, Samsun, Turkey, 7Physical Medicine and Rehabilitation, Ondokuz Mayis University, Samsun, Turkey, 8PM&R AND RHEUMATOLOGY, Karadeniz Tecnical University, Faculty of Medicine, TRABZON, Turkey, 9Physical Treatment and Rehabilitation, Istanbul Physical Treatment and Rehabilitation Training and Research Hospital, Istanbul, Turkey, 10Rheumatology, Physical Medicine and Rheabilitation, Antalya Education and Research Hospital, Antalya, Turkey, 11Rheumatology, Physical Medicine&Rehabilitation, Antalya Education and Research Hospital, Antalya, Turkey, 12Physical Med & Rehab, Hacettepe Univ, Ankara, Turkey

    Background/Purpose: The impact of  rheumatoid arthritis (RA) and ankylosing spondylitis (AS)  on paid work is measured on the basis of employed people missing time from…
  • Abstract Number: 2499 • 2014 ACR/ARHP Annual Meeting

    Early Response Indicator early Predicts Clinical Response to Certolizumab in Rheumatoid Arthritis Patients

    Massimiliano Cazzato1, Laura Bazzichi2, Stefano Bombardieri3 and Camillo Giacomelli4, 1Internal Medicine, Rheumatology Unit, Pisa, Italy, 2Santa Chiara Hospital, Rheumatology, pisa, Italy, 3Rheumatology Unit, Pisa, Italy, 4Rheumatology, pisa, Italy

    Background/Purpose In the last few years the introduction of biological agents has radically changed the clinical outcome of patients with Rheumatoid Arthritis (RA). However, no…
  • Abstract Number: 824 • 2014 ACR/ARHP Annual Meeting

    Impact of Oral Glucocorticoid Therapy on Mortality in Patients with Rheumatoid Arthritis and Diabetic Mellitus

    Mohammad Movahedi and William G Dixon, Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom

    Background/Purpose Glucocorticoid (GC) therapy is known to increase the risk of new-onset type 2 diabetes mellitus (DM). Furthermore, GC therapy increases blood glucose in diabetic…
  • Abstract Number: 2380 • 2014 ACR/ARHP Annual Meeting

    Durability of First Biologic Is Not Influenced By Initial/Early DAS28

    Gina Rohekar1, Binu Jacob2, Janet E. Pope3 and Claire Bombardier4, 1Rheumatology, St. Joseph's Hospital, London, ON, Canada, 2University Health Network, Toronto General Research Institute, Toronto, ON, Canada, 3Medicine, Western University, London, ON, Canada, 4Rheumatology, University of Toronto, Toronto, ON, Canada

    Background/Purpose:   The Ontario Best Practices Research Initiative (OBRI) collects data on RA treatment in a real-world setting.  Patients are enrolled and prospectively followed to…
  • Abstract Number: 424 • 2014 ACR/ARHP Annual Meeting

    The Comparison Between Physical and Ultrasound Joint Examination for the Hand Joints in Patients with Rheumatoid Arthritis

    Norihide Hayashi1, Takehisa Ogura2, Ayako Hirata2, Rie Kujime3, Munetsugu Imamura1, Sayaka Takenaka3, Kennosuke Mizushina3, Sumie Nakahashi3, Hideki Ito1, Naoko Yamashita3 and Hideto Kameda1, 1Div Rheumatol, Dep Intern Med, Toho Univ, Tokyo, Japan, 2Department of Rheumatology, Toho Univ, Tokyo, Japan, 3Toho Univ, Tokyo, Japan

    Background/Purpose To establish the importance of joint examination by ultrasound (US) in daily clinical practice of patients with rheumatoid arthritis (RA), we compared the US…
  • Abstract Number: 2384 • 2014 ACR/ARHP Annual Meeting

    Factors Associated with Methotrexate Treatment Duration, Including Subcutaneous Use, in Patients with Rheumatoid Arthritis: Observations from the VA Database

    Bernard Ng, Rheumatology, U.S. Department of Veterans' Affairs- Puget Sound Healthsystem, Seattle, WA

    Background/Purpose: A previous analysis of RA patients in national administrative databases of the Department of Veterans Affairs (VA) suggested that injectable MTX was associated with…
  • Abstract Number: 430 • 2014 ACR/ARHP Annual Meeting

    Minimally Important Difference in the European Quality of Life-Five Dimensions in Patients with Rheumatoid Arthritis

    Daisuke Hoshi, Eiichi Tanaka, Eisuke Inoue, Kumi Shidara, Yoko Shimizu, Akiko Kobayashi, Naoki Sugimoto, Eri Sato, Yohei Seto, Ayako Nakajima, Shigeki Momohara, Atsuo Taniguchi and Hisashi Yamanaka, Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan

    Background/Purpose Patient-reported outcomes (PROs) have been recognized as important in evaluating disease status of rheumatoid arthritis (RA). The minimally important difference (MID) in PROs has…
  • Abstract Number: 2366 • 2014 ACR/ARHP Annual Meeting

    Effectiveness, Tolerability, and Safety of Subcutaneous Methotrexate in Early Rheumatoid Arthritis: Clinical Data from the St. Gallen Cohort

    Ruediger Mueller1, Johannes von Kempis1, Michael H Schiff2 and Sarah Haile3, 1Rheumatology, St. Gallen Hospital, CH- 9007 St.Gallen, Switzerland, 2University of Colorado, Denver, CO, 3Division of Biostatistics, Institute for Social and Preventive Medicine,, University of Zurich, Switzerland, Zurich, Switzerland

    Background/Purpose: MTX is the cornerstone of RA treatment, although limitations of systemic exposure of oral MTX may affect its efficacy. Subcutaneous (SC) MTX has greater…
  • Abstract Number: 265 • 2014 ACR/ARHP Annual Meeting

    Prevalence of Medicinal Marijuana Use Among 1000 Rheumatology Patients Attending a Community-Based Rheumatology Clinic: A Prospective Cross-Sectional Study

    Peter A. Ste-Marie1, Yoram Shir1, Emmanouil Rampakakis2, John S. Sampalis2,3, Martin Cohen4, Michael Starr5, Mark A Ware1 and Mary-Ann Fitzcharles6, 1Alan Edwards Pain Management Unit, McGill University Health Centre, Montreal, QC, Canada, 2JSS Medical Research, Montreal, QC, Canada, 3Jewish General Hospital, McGill University, Montreal, QC, Canada, 4Rheumatology, Mcgill University Health Centre, Montreal, QC, Canada, 5Rheumatology, McGill University Health Centre, Montreal, QC, Canada, 6Rheumatology and Pain Management Unit, McGill University Health Centre, Montreal, QC, Canada

    Background/Purpose:  With a worldwide groundswell of interest in cannabinoids as a possible treatment option for persons with rheumatic diseases, and with few pharmacologic cannabinoid options…
  • « Previous Page
  • 1
  • …
  • 5
  • 6
  • 7
  • 8
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology